Videos
September 21, 2022

Dr. Shaun Grannis on data surveillance of post-COVID conditions

Dr. Shaun Grannis on data surveillance of post-COVID conditions

Regenstrief Vice President for Data and Analytics Shaun Grannis, M.D., M.S., discusses the questions that will be investigated in the Institute’s new CDC-funded study on post-COVID conditions.

Read the full release

Transcript:
We’ve been focusing for the last couple of years on how to identify patients with COVID, how to prevent it, understanding what treatment methodologies were helpful in addressing the immediate case of COVID. But there are questions about how does COVID impact individuals over time. We don’t have any good data on that. Sometimes this condition is called long COVID. Sometimes we call it post-COVID conditions.

But it’s important to understand what type of effect this new virus has on individuals long term. And this virus has behaved in a way that’s still, I think, intriguing and perhaps sometimes confusing to individuals, in that the virus significantly impacted individuals with the older they were or the with more, the more co-morbidities they had. But in the younger populations, it was significantly less impactful.

In fact, it was safer to get COVID if you were a child than if you were to get influenza. So, the behaviors of this virus are still not fully understood, and I think we need to be able to track those patterns over time and understand, you know, increased risk of mental health, depression, those sorts of things, but also, is there an increase of cardiovascular disease, increased risk of diabetes?

What if you were diabetic, got COVID? How does your diabetes progress compared to somebody who may have been protected from COVID with a vaccine? So there are a lot of questions that we need to answer, and that’s why this program exists.

Related News

Johanne Eliacin and Sophia Wang

Factors influencing participation of Black and White Americans in Alzheimer’s disease biomarker research

Regenstrief researcher leads study of barriers to participation and drivers of engagement The use of Alzheimer’s disease (AD) biomarkers

Multi-state study reports COVID-19 mRNA vaccines protective during Omicron BA.4/BA.5 predominance

Multi-state study reports COVID-19 mRNA vaccines protective during Omicron BA.4/BA.5 predominance

Study also finds less severe disease during BA.4/BA.5 predominance compared to earlier Omicron variants A multi-state study from the

Dr. Kurt Kroenke at the 2023 Indianapolis Business Journal's Health Care Heroes Awards Breakfast

IBJ Honors Regenstrief research scientist with Heath Care Hero Award 

The Indianapolis Business Journal (IBJ) honored Regenstrief Research Scientist Kurt Kroenke, M.D., MACP, as a Health Care Hero at

LOINC Logo

LOINC 2.74 Release Webinar scheduled for spring 2023

LOINC® from Regenstrief Institute will host an educational webinar for the February 2023 2.74 release of new concepts, scheduled